Rodriguez Javier reported option exercise involving 17,500 derivative units of BioXcel Therapeutics, Inc. at $0.00 for $0 on May 4, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
See Remarks
See Remarks
Filed May 22, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
17,500Restricted Stock Units
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
52,500Direct
Trade date
May 4, 2026Option exercise
Filed
May 22, 2026, 7:02 PM ET18-day reporting delay
Accession
0001104659-26-065839Code M · Transaction 384012
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 20, 2026Sell6,560$1.08−$7,111.04Trade 384011
May 4, 2026Option exercise17,500——Trade 384010
3 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 18 calendar days after the transaction date.

BTAI price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BTAI · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +4.4%1w ago −3.5%1d ago +6.2%
Returns since7d +3.5%30d +6.2%90d −29%180d1y

Footnotes in full

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2026 solely to cover taxes due in connection with the vesting of restricted stock units. F3: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.07 to $1.09. The Reporting Person undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4: On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the "Vesting Commencement Date"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.